Stark H, Hüls A, Ligneau X, Arrang J M, Schwartz J C, Schunack W
Institut für Pharmazie I Freie Universität Berlin, Germany.
Pharmazie. 1997 Jul;52(7):495-500.
This study was performed in order to develop new leads for antagonists of the histamine H3-receptor subtype. omega-(1 H-Imidazol-4-yl)alkyl derivatives with ester, ketone or alcohol functionality in the side chain were synthesized and tested concerning their H3-receptor antagonist activity on synaptosomes of rat cerebral cortex. The novel compounds, which possess no nitrogen-containing polar group in the side chain of the imidazole moiety, presented moderate to high antagonist potency in vitro. In this series 3-(1 H-imidazol-4-yl)propyl-3-cyclopentylpropanoate (4) was the most potent compound in vitro with -log Ki = 8.5. Unfortunately, no central antagonist H3-receptor activity was detectable for ester derivatives in the in vitro H3-receptor assay based upon measurement of brain N tau-methylhistamine levels after p.o. administration to mice. Some of these novel antagonists are useful tools for investigations on ligand-receptor interaction because of their distinct receptor activities. On the other hand, the ketone derivative 1-(1 H-imidazol-4-yl)-7-phenyl-4-heptanone (9) in vitro presented an ED50-value of 3.5 +/- 1.5 mg/kg p.o. thus proving to be a new lead for further drug investigations. The most potent compounds in vitro and in vivo also showed high H3-receptor selectivity when tested at other histamine receptor subtypes.
本研究旨在开发组胺H3受体亚型拮抗剂的新先导化合物。合成了侧链带有酯、酮或醇官能团的ω-(1H-咪唑-4-基)烷基衍生物,并测试了它们对大鼠大脑皮质突触体的H3受体拮抗活性。这些新型化合物在咪唑部分的侧链中没有含氮极性基团,在体外表现出中度到高度的拮抗效力。在该系列中,3-(1H-咪唑-4-基)丙基-3-环戊基丙酸酯(4)是体外效力最强的化合物,-log Ki = 8.5。遗憾的是,在基于口服给药小鼠后脑Nτ-甲基组胺水平测定的体外H3受体试验中,酯衍生物未检测到中枢H3受体拮抗活性。这些新型拮抗剂中的一些因其独特的受体活性,是研究配体-受体相互作用的有用工具。另一方面,酮衍生物1-(1H-咪唑-4-基)-7-苯基-4-庚酮(9)在体外口服给药时的ED50值为3.5±1.5 mg/kg,因此被证明是进一步药物研究的新先导化合物。体外和体内效力最强的化合物在测试其他组胺受体亚型时也表现出高H3受体选择性。